The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and ...

The bad news keeps on creeping toward Vyne Therapeutics’ BET inhibitor platform. | Weeks after the biotech gave up on a ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

Veteran clinical research leader Melissa Holbrook has found her next permanent role. | Veteran clinical research leader ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...

As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through ...

Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...